HC Wainwright Has Bearish Forecast for KYMR Q3 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.04) for the quarter, down from their previous forecast of ($0.69). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($4.22) EPS, FY2028 earnings at ($4.32) EPS, FY2029 earnings at ($3.70) EPS and FY2030 earnings at $0.22 EPS.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter last year, the firm posted ($0.95) EPS. The firm’s revenue for the quarter was up 465.2% on a year-over-year basis.

KYMR has been the subject of a number of other research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 target price on shares of Kymera Therapeutics in a report on Thursday. B. Riley Financial increased their price target on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price objective for the company from $106.00 to $115.00 in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They set a “hold” rating and a $120.00 price objective for the company. Finally, Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Kymera Therapeutics Stock Up 1.0%

NASDAQ KYMR opened at $108.58 on Monday. The company has a market cap of $9.03 billion, a PE ratio of -33.51 and a beta of 1.95. Kymera Therapeutics has a 52 week low of $36.65 and a 52 week high of $130.05. The firm’s 50-day simple moving average is $101.92 and its two-hundred day simple moving average is $89.21.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP increased its holdings in shares of Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Finally, BlackRock Inc. bought a new stake in Kymera Therapeutics in the 2nd quarter worth about $635,067,000.

Insider Buying and Selling at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 77,109 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Noah Goodman sold 3,389 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total transaction of $387,328.81. Following the transaction, the insider directly owned 47,179 shares of the company’s stock, valued at $5,392,087.91. This represents a 6.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,604,813 shares of company stock worth $387,557,004. Insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.